Mitochondrial Plaques: A New Discovery in Alzheimer’s Research
Recent findings from the University of Minnesota have identified a novel type of brain plaque that could change the understanding of Alzheimer’s disease. Published in Nature Neuroscience, this research introduces “mitochondrial plaques,” found in both preclinical models and human brain tissues. These plaques may emerge earlier than the known beta-amyloid plaques, suggesting new directions for treatment strategies.
Mitochondrial Plaques and Disease Progression
Alzheimer’s disease leads to a gradual decline in brain cells and cognitive abilities. Historically, research emphasized beta-amyloid plaques and neurofibrillary tangles as the disease’s primary markers. The newly discovered plaques appear to form independently and may be present at the disease’s earliest stages. They contain high levels of amyloid precursor protein, which is crucial in forming beta-amyloid. As the disease progresses, mitochondrial plaques often appear alongside traditional plaques, indicating a potential contribution to classic brain changes.
“This discovery identifies mitochondrial plaques as a previously unrecognized feature of Alzheimer’s disease,” stated Paul Robbins, a professor at the University of Minnesota Medical School.
Shifting Focus in Alzheimer’s Research
Unlike traditional amyloid plaques, these new plaques may directly impact neurons, presenting a novel target for treatments. The findings suggest that Alzheimer’s-related brain changes could begin earlier and through different processes. Despite the promise, further research is required to grasp the discovery’s full significance. Laura Bojarskaite, a neuroscientist at the University of Oslo, emphasized that more studies must validate these findings to reshape the understanding of Alzheimer’s inception.
The research points to a need for focusing on intracellular processes occurring within neurons, shifting attention from the traditionally studied extracellular plaques. Bojarskaite remarked on the importance of determining whether mitochondrial plaques actively contribute to neurodegeneration or merely reflect stressed neurons.
Implications for Future Research and Treatment
The study also raises questions about mitochondrial dysfunction in Alzheimer’s disease. Researchers are exploring whether existing mitochondrial issues trigger the disease or are a result of other ongoing changes. Future research might determine if mitochondrial plaques could serve as early biomarkers, enhancing early diagnosis and intervention. There is potential for therapies aimed at preserving mitochondrial function rather than targeting amyloid exclusively.
Bojarskaite cautioned that significant hurdles must be overcome. Replication of results, observation in living patients, and prediction of disease progression are essential before clinical applications can be developed. While promising, these findings should not yet influence current practice.
The University of Minnesota team is focused on identifying biomarkers associated with mitochondrial plaques and screening for drugs to prevent accumulation. Such work could reveal whether these structures play a direct role in Alzheimer’s and if targeting them could slow disease progression.
Reference: Xiuli Dan et al, Mitochondrial accumulation and lysosomal dysfunction result in mitochondrial plaques in Alzheimer’s disease, Nature Neuroscience (2026). DOI: 10.1038/s41593-026-02390-1